Keywords: adventrx, treats, first, subject, cofactor, ph, iib
Adventrx treats first subject in CoFactor Ph IIb trial
Article | 06 June 2005
US group Adventrx Pharmaceuticals has initiated patient treatment in its 300-patient, international, randomized, controlled, Phase IIb clinical trial investigating its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
